- Home
- QVCGB vs AKRO Comparison
QVCGB vs AKRO Comparison
Compare QVCGB & AKRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QVCGB
- AKRO
- Stock Information
- Founded
- QVCGB 1991
- AKRO 2017
- Country
- QVCGB United States
- AKRO United States
- Employees
- QVCGB N/A
- AKRO N/A
- Industry
- QVCGB
- AKRO Biotechnology: Pharmaceutical Preparations
- Sector
- QVCGB
- AKRO Health Care
- Exchange
- QVCGB NYSE
- AKRO Nasdaq
- Market Cap
- QVCGB 2.7B
- AKRO 2.8B
- IPO Year
- QVCGB N/A
- AKRO 2019
- Fundamental
- Price
- QVCGB $5.51
- AKRO $37.63
- Analyst Decision
- QVCGB
- AKRO Strong Buy
- Analyst Count
- QVCGB 0
- AKRO 9
- Target Price
- QVCGB N/A
- AKRO $76.29
- AVG Volume (30 Days)
- QVCGB 46.6K
- AKRO 1.3M
- Earning Date
- QVCGB 05-07-2025
- AKRO 05-09-2025
- Dividend Yield
- QVCGB N/A
- AKRO N/A
- EPS Growth
- QVCGB N/A
- AKRO N/A
- EPS
- QVCGB N/A
- AKRO N/A
- Revenue
- QVCGB $10,037,000,000.00
- AKRO N/A
- Revenue This Year
- QVCGB $2.89
- AKRO N/A
- Revenue Next Year
- QVCGB $0.45
- AKRO N/A
- P/E Ratio
- QVCGB N/A
- AKRO N/A
- Revenue Growth
- QVCGB N/A
- AKRO N/A
- 52 Week Low
- QVCGB $2.00
- AKRO $17.86
- 52 Week High
- QVCGB $18.74
- AKRO $58.40
- Technical
- Relative Strength Index (RSI)
- QVCGB N/A
- AKRO 43.61
- Support Level
- QVCGB N/A
- AKRO $36.46
- Resistance Level
- QVCGB N/A
- AKRO $39.13
- Average True Range (ATR)
- QVCGB 0.00
- AKRO 3.04
- MACD
- QVCGB 0.00
- AKRO 0.06
- Stochastic Oscillator
- QVCGB 0.00
- AKRO 57.38
About QVCGB QVC GROUP INC
QVC Group Inc is a live social shopping company with six retail brands QVC, HSN, Ballard Designs, Frontgate, Garnet Hill, Grandin Road, and other minority interests. QVC offers assortment of ,quality merchandise and classifies its products into six groups: home, apparel, beauty, accessories, electronics and jewelry. The company has three reportable segments: QxH, QVC International, and CBI. Majority of revenue is from Home products, from QxH segment. Company also operates in Japan, Germany and Other foreign countries.
About AKRO Akero Therapeutics Inc.
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis (MASH), or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that have the potential to address the core processes underlying NASH pathogenesis.